Abstract
What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
Original language | English |
---|---|
Pages (from-to) | 621-623 |
Number of pages | 3 |
Journal | Journal of Clinical Pharmacy and Therapeutics |
Volume | 42 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct 1 2017 |
Keywords
- gastrectomy
- hepatitis C virus
- ledipasvir
- pharmacokinetics
- sofosbuvir
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)